E 13 (Griseofulvin (ultramicrocrystalline) 125 mg)
Pill imprint E 13 has been identified as Griseofulvin (ultramicrocrystalline) 125 mg.
Griseofulvin is used in the treatment of tinea capitis; onychomycosis, toenail; dermatophytosis; tinea corporis; onychomycosis, fingernail (and more), and belongs to the drug class miscellaneous antifungals. Risk cannot be ruled out during pregnancy. Griseofulvin 125 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- E 13
- Strength:
- 125 mg
- Color:
- White
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Miscellaneous antifungals
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Sigmapharm Laboratories, LLC
More about griseofulvin
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 12 Reviews – Add your own review/rating
- Drug class: miscellaneous antifungals
Consumer resources
- Griseofulvin microsize oral suspension
- Griseofulvin microsize tablets
- Griseofulvin ultramicrosize tablets
- Griseofulvin
- Griseofulvin (Advanced Reading)
Other brands: Gris-PEG, Grifulvin V, Fulvicin U/F, Fulvicin P/G
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
